Honnemyr Maria, Bruserud Øystein, Brenner Annette K
Section for Hematology, Department of Clinical Science, Haukeland University Hospital, University of Bergen, 5021, Bergen, Norway.
Department of Medicine, Haukeland University Hospital, Bergen, Norway.
J Cancer Res Clin Oncol. 2017 Oct;143(10):1985-1998. doi: 10.1007/s00432-017-2458-7. Epub 2017 Jun 19.
Acute myeloid leukemia (AML) cells show constitutive release of matrix metalloproteases and their inhibitors. We now investigated this constitutive release of protease/protease regulators associated with carcinogenesis (ADAM12, uPA, cystatin B), angiogenesis (serpin E1, uPA, CD147), cancer cell migration (uPA, cystatin C), coagulation (ADAM TS13, serpin C1), inflammation (fetuin A, caspase 1, cystatin C), monocytic differentiation (CFD) or regulation of hematopoiesis (neutrophil elastase).
AML blasts from 79 consecutive patients were cultured in serum-free medium and mediator levels determined in culture supernatants.
Detectable release of serpin C1 and E1, cystatin B and C, CD147 and uPA was seen for most patients. These mediators together with fetuin A, caspase 1, and CFD were included in a hierarchical clustering analysis and three patient subsets were identified (high, intermediate, and low release). High levels were associated with monocytic differentiation. Global gene expression analyses showed increased levels of several zinc finger proteins for low-release patients and high expression of several cell surface molecules, ATPases, and calcium-binding proteins for high-release patients. Constitutive release of several mediators was also seen for normal hematopoietic cells and mesenchymal stem cells. In cocultures of the latter and AML blasts, the release level for most mediators was altered to resemble the levels of the mesenchymal cells cultured alone.
Differences in constitutive release of protease/protease regulators are a part of the disease heterogeneity in AML.
急性髓系白血病(AML)细胞表现出基质金属蛋白酶及其抑制剂的组成性释放。我们现在研究了与致癌作用(ADAM12、尿激酶型纤溶酶原激活物(uPA)、胱抑素B)、血管生成(丝氨酸蛋白酶抑制剂E1、uPA、CD147)、癌细胞迁移(uPA、胱抑素C)、凝血(凝血酶敏感蛋白13(ADAMTS13)、丝氨酸蛋白酶抑制剂C1)、炎症(胎球蛋白A、半胱天冬酶1、胱抑素C)、单核细胞分化(补体因子D(CFD))或造血调节(中性粒细胞弹性蛋白酶)相关的蛋白酶/蛋白酶调节剂的这种组成性释放。
对79例连续患者的AML原始细胞在无血清培养基中培养,并测定培养上清液中的介质水平。
大多数患者的培养上清液中可检测到丝氨酸蛋白酶抑制剂C1和E1、胱抑素B和C、CD147和uPA的释放。这些介质与胎球蛋白A、半胱天冬酶1和CFD一起进行层次聚类分析,确定了三个患者亚组(高释放、中释放和低释放)。高水平与单核细胞分化相关。全基因组表达分析显示,低释放患者的几种锌指蛋白水平升高,高释放患者的几种细胞表面分子、ATP酶和钙结合蛋白高表达。正常造血细胞和间充质干细胞也存在几种介质的组成性释放。在后者与AML原始细胞的共培养中,大多数介质的释放水平发生改变,类似于单独培养的间充质细胞的水平。
蛋白酶/蛋白酶调节剂组成性释放的差异是AML疾病异质性的一部分。